Trials / Available
AvailableNCT05491928
Treatment of Metastatic Cancer in Terminally Diagnosed Patients
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Matrix Biomed, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The objective is to provide terminally diagnosed patients with a last line of treatment while improving overall quality of life. Tempol can be added to any chemotherapy regimen to potentially reduce side effects and overcome chemoresistance.
Detailed description
The objective is to provide terminally diagnosed patients assigned to palliative care and palliative chemotherapy a last line treatment with Tempol. In vivo studies have shown Tempol to work synergistically with a number of chemotherapy agents increasing treatment response and reducing chemoresistance. Additionally, Tempol has been shown to provide protection to non-cancerous cells allowing for increased chemotherapy dosing by reducing side effects. Tempol inhibits HIF-1/VEGF among others in cancerous cells while upregulating GSH/NrF2 among others in non-cancerous cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tempol | Tempol will be given as an adjunct to chemotherapy. |
Timeline
- First posted
- 2022-08-08
- Last updated
- 2022-09-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05491928. Inclusion in this directory is not an endorsement.